1	Neonatal Paenibacilliosis: Paenibacillus thiaminolyticus as a Novel Cause of Neonatal Sepsis
2	with High Risk of Sequelae in Uganda
3	Jessica E. Ericson <sup>1</sup> *, Kathy Burgoine <sup>2, 3, 4, 5</sup> *, Elias Kumbakumba <sup>6</sup> *, Moses Ochora <sup>6</sup> *, Christine
4	Hehnly <sup>1</sup> *, Francis Bajunirwe <sup>6</sup> , Joel Bazira <sup>6</sup> , Claudio Fronterre <sup>7</sup> , Cornelia Hagmann7, Abhaya V.
5	Kulkarni <sup>8</sup> , M. Senthil Kumar <sup>9</sup> , Joshua Magombe <sup>10</sup> , Edith Mbabazi-Kabachelor <sup>10</sup> , Sarah U. Morton <sup>11</sup> ,
6	Mercedeh Movassagh <sup>9</sup> , John Mugamba <sup>10</sup> , Ronald Mulondo <sup>10</sup> , Davis Natukwatsa <sup>10</sup> , Brian Nsubuga
7	Kaaya <sup>10</sup> , Peter Olupot-Olupot <sup>4,5</sup> , Justin Onen <sup>10</sup> , Kathryn Sheldon <sup>1</sup> , Jasmine Smith <sup>1</sup> , Paddy Ssentongo <sup>1</sup> ,
8	Peter Ssenyonga <sup>10</sup> , Benjamin Warf <sup>11</sup> , Emmanuel Wegoye <sup>10</sup> , Lijun Zhang <sup>12</sup> , Julius Kiwanuka <sup>6</sup> † Δ, Joseph
9	N. Paulson <sup>13</sup> <sup>†</sup> , James R. Broach <sup>1</sup> <sup>†</sup> , Steven J. Schiff <sup>14</sup> <sup>†</sup>
10	*, † Contributed Equally, $\Delta$ Deceased
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	<ul> <li><sup>1</sup>Penn State College of Medicine, Hershey, PA, USA</li> <li><sup>2</sup>Department of Paediatrics and Child Health, Mbale Regional Referral Hospital, Mbale, Uganda</li> <li><sup>3</sup>Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom</li> <li><sup>4</sup>Mbale Clinical Research Institute, Mbale Regional Referral Hospital, Mbale, Uganda</li> <li><sup>5</sup>Busitema University, Busitema, Uganda</li> <li><sup>6</sup>Mbarara University of Science and Technology, Mbarara, Uganda</li> <li><sup>7</sup>Lancaster University, Lancaster, United Kingdom</li> <li><sup>8</sup>Hospital for Sick Children, University of Toronto, Toronto, Canada</li> <li><sup>9</sup>Harvard T.H. Chan School of Public Health, Dana Farber Cancer Institute, Boston, MA, USA</li> <li><sup>10</sup>CURE Children's Hospital of Uganda, Mbale, Uganda</li> <li><sup>11</sup>Harvard Medical School, Boston, MA, USA</li> <li><sup>12</sup>Case Western Reserve University School of Medicine, Cleveland, OH, USA</li> <li><sup>13</sup>N-Power Medicine, Inc., Redwood City, CA, USA</li> <li><sup>14</sup>Yale University School of Medicine, New Haven, CT, USA</li> </ul>
26 27 28 29 30 31 32 33 34 35 36	<b>Abstract</b> <i>Paenibacillus thiaminolyticus</i> may be an underdiagnosed cause of neonatal sepsis. We prospectively enrolled a cohort of 800 neonates presenting with a clinical diagnosis of sepsis at two Ugandan hospitals. Quantitative polymerase chain reaction specific to <i>P. thiaminolyticus</i> and to the <i>Paenibacillus</i> genus were performed on the blood and cerebrospinal fluid (CSF) of 631 neonates who had both specimen types available. Neonates with virus detected in either specimen type were considered to potentially have paenibacilliosis, (37/631, 6%). We described antenatal, perinatal, and neonatal characteristics, presenting signs, and 12-month developmental outcomes for neonates with paenibacillosis vs. clinical sepsis. Median age at presentation was 3 (interquartile range 1, 7) days. Fever (92%), irritability (84%) and seizures (51%) were common. Eleven (30%) had an adverse outcome: 5 (14%) neonates died during the first year of life; 5 of 32 (16%) survivors developed postinfectious hydrocephalus and one (3%) additional survivor

- had neurodevelopmental impairment without hydrocephalus. These results highlight the need to consider
- 38 local pathogen prevalence and the possibility of unusual pathogens when determining antibiotic choice
- 39 for neonatal sepsis.
- 40

Neonatal sepsis is a leading cause of early childhood death worldwide.<sup>1,2</sup> Affected infants are
disproportionately from low-resource settings.<sup>2</sup> Survivors of neonatal sepsis have an increased risk of
neurodevelopmental impairment<sup>3,4</sup>, hydrocephalus<sup>5</sup> and cerebral palsy.<sup>6</sup> Effective antibiotic therapy relies
on identification of the causative pathogen or, in the absence of this information, empirical therapy that is
broad enough to provide effective coverage of the most likely pathogens.<sup>6</sup>

In low-resource settings, blood and cerebrospinal fluid cultures are often unavailable or uninformative.<sup>7</sup> Cultures can be negative for a variety of reasons including low sample volume and technical limitations.<sup>8</sup> Some pathogens are unculturable or are difficult to culture using routine culture methods. Culture-independent methods to identify causative pathogens have recently become possible due to advances in molecular diagnostics. Because of their cost and technical requirements, these methods are not widely available and have only rarely been used to identify pathogens affecting neonates in lowresource settings.<sup>9,10</sup>

Current international guidelines recommend the combination of ampicillin and gentamicin as
first-line empirical antibiotic therapy for neonates with sepsis.<sup>11</sup> However, in regions where antibiotic
resistance is common, these antibiotics are not the ideal treatment for many neonatal infections.<sup>12-14</sup>
Without local culture and antibiotic susceptibility testing, the risk of antibiotic resistance is unknown; in
these cases, ampicillin and gentamicin may be inadequate treatment.<sup>15,16 15,16 15,16 15,16 15,16 15,16
</sup>

58 In previous work, using targeted metagenomics, we found 41% of infants with postinfectious hydrocephalus, a common sequela of NS in Uganda, had a *Paenibacillus spp* infection.<sup>15,17</sup> We sought to 59 60 describe the clinical syndrome of neonatal Paenibacillus infection among Ugandan neonates presenting 61 with clinical signs of sepsis, to report 12-month outcomes for infants with this novel infection and to 62 compare patient characteristic and outcomes for infants with Paenibacillus infection compared to infants 63 with clinical sepsis without Paenibacillus detected. We hypothesized that infants with Paenibacillus 64 detected would be more likely to have the composite outcome of postinfectious hydrocephalus, death or 65 neurodevelopmental impairment than those without Paenibacillus detected.

#### 66 Methods

### 67 Study Population

68 Ugandan neonates ( $\leq 28$  days of age) previously enrolled in a parent study were evaluated for 69 inclusion in this subanalysis focused on Paenibacillus infection. The parent study enrolled 800 neonates 70 presenting to two regional referral hospitals with clinical signs of neonatal sepsis (fever, poor feeding and 71 lethargy; hypothermia, poor feeding, and lethargy; seizures and/or bulging fontanelle, poor feeding, and 72 fever) were recruited. The study sites were, Mbale Regional Referral Hospital in Eastern Uganda, and 73 Mbarara Regional Referral Hospital in Western Uganda. Neonates born at a gestational age < 37 weeks or 74 < 2000 grams birthweight, and those who had been diagnosed with birth asphyxia or hypoxic ischemic 75 encephalopathy were excluded. Following informed written consent, blood and cerebrospinal fluid were 76 collected from each neonate using aseptic technique. Infants were eligible for this subanalysis if they had 77 sufficient blood and CSF to perform qPCR for *Paenibacillus* genus and *P. thiaminolyticus* (N=631).

## 78 Laboratory Analysis

79 An aliquot of each was collected into DNA/RNA preservative (DNA/RNA Shield, Zymo Corporation) 80 and frozen at -80° C. Additional aliquots of blood and CSF were processed in the local clinical laboratory 81 for standard-of-care clinical tests. Once the entire cohort had been enrolled, the frozen samples were 82 transferred to Penn State University for processing. CSF was available for 631/800 (79%) of the neonates 83 enrolled. For these 631, we performed quantitative polymerase chain reaction (qPCR) on the blood and 84 CSF using primers specific to both the *Paenibacillus* genus and *P. thiaminolyticus*. Neonates with 85

86 Demographics, birth history, clinical signs at presentation and during the hospital stay, results of 87 laboratory tests performed as part of clinical care and antibiotics administered were abstracted from each 88 infant's medical record. In Uganda, current clinical guidelines recommend that the umbilical cord stump 89 receive no care (dry cord care) or be cleansed with chlorhexidine (Umbigel<sup>TM</sup>). Mothers were asked to

detection of virus using either test were considered to have possible paenibacilliosis.

90	indicate how they cared for the neonate's cord stump at home including any substances applied to the
91	cord stump prior to presentation. The presence of seizure-like movements was considered to represent
92	seizures; no electroencephalograms were performed. Fever was defined as a temperature ≥38° C.
93	Infants underwent developmental assessments at 2 months, 6 months and 12 months of age using
94	the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III). <sup>18</sup> Population-normalized
95	BSID-III scores range from 1 to 19 with a population mean of 10, and a standard deviation (SD) of 3.
96	Neurodevelopmental impairment (NDI) was defined as a BSID-III score < -2SD on any of the subscales.
97	We compared the demographic characteristics, presenting clinical signs, antibiotic treatment and
98	clinical course for patients with neonatal paenibacillosis to septic neonates without P. thiaminolyticus
99	detected using Fisher's exact test for proportions and Wilcoxon rank-sum test for continuous variables.
100	Similarly, we compared the proportion of patients with and without paenibacilliosis who experienced in-
101	patient death, infant death (death between birth and 1 year of age), postinfectious hydrocephalus (PIH),
102	NDI, and the composite of infant death, PIH or NDI during the first 12 months of age using Fisher's exact
103	test. Finally, for infants with paenibacilliosis, we compared the proportion of patients with fever,
104	irritability, seizure, tachypnea, respiratory distress, umbilical cord discharge, hypertonia, tachycardia,
105	bulging fontanelle and stiff neck between the two study sites. Missingness was uncommon and no
106	adjustment or imputation was undertaken.
107	Neonates with PIH were referred to CURE Children's Hospital of Uganda, a neurosurgical
108	specialty hospital located in Mbale for further management. Additional specimens of CSF were collected
109	as part of the neurosurgical evaluation. Each specimen was split into two aliquots: one that was collected

into DNA/RNA preservative (DNA/RNA Shield, Zymo Corporation) and frozen at -80° C and one that
was frozen without preservative. An additional 61 infants with PIH had their CSF processed in the same

112 manner. The fresh frozen samples were thawed and 1 mL of CSF from each patient was inoculated into a

113 BD BACTEC lytic anaerobic medium blood culture bottle supplemented with 1 mL of defibrinated horse

114 blood (Thermo Scientific). Culture bottles were incubated in a BD BACTECTM FX instrument and

115	monitored for bacterial growth for up to 14 days. Culture bottles that were positive for bacterial growth
116	were subcultured on BD BBLTM Chocolate II and CDC Anaerobe 5% Sheep Blood agar plates and
117	incubated at 37° C under anaerobic conditions (Anoxomat, Advanced Instruments). Culture bottles that
118	remained negative after 14 days were also subcultured under anaerobic conditions though none of these
119	resulted in bacterial growth. All subsequent culturing after initial anaerobic conditions was done
120	aerobically. Three CSF samples were positive for growth in culture bottles. As previously described,
121	colonies from subculture plates were used for Gram stain, organism identification by MALDI-TOF,
122	biochemical testing, and antimicrobial susceptibility testing. Biochemical testing was performed using
123	API 50 CH strip following manufacturers protocol. Susceptibility testing and interpretations were
124	performed by E-test method using Clinical and Laboratory Standards Institute (CLSI) guidelines.
125	This study was approved by the Human Subjects Protection Program at The Pennsylvania State
126	University, Pennsylvania, United States, by CURE Children's Hospital of Uganda Institutional Review
127	Board, the Mbarara University of Science and Technology Research Ethics Committee, and with
128	oversight of the Ugandan National Council on Science and Technology. Informed written consent was
129	obtained from each patient's mother prior to enrollment. All data produced in the current study are
130	available upon reasonable request to the authors and will be made publicly available once the parent
131	neonatal sepsis study is published.

132 **Results** 

# 133 Clinical Epidemiology of Paenibacillosis

Six percent (37/631) of neonates with clinical sepsis had PCR evidence of *Paenibacillus*infection. CSF PCR was positive in most cases, 35/631 (6%) patients; 1/35 (3%) of these also had a
positive blood PCR. Two additional patients had a positive blood PCR but negative CSF PCR
(Supplemental Table 1).

138	Postnatal age at presentation was similar for neonates with and without paenibacillosis, median
139	age 3 (IQR 1, 7) days and 2 (1, 4) days, respectively, P=0.129 (Table 1). Most neonates with
140	paenibacillosis were born vaginally (73%) in a healthcare facility (hospital, lower level health center or
141	private clinic) (78%). However, when compared to infants without paenibacilliosis, infants with
142	paenibacilliosis detected were significantly more likely to be born at home, 6% vs. 22%, respectively,
143	P<0.01 and to have received non-recommended cord stump care, 19% vs. 38%, respectively, P=0.01.
144	Neonates with paenibacilliosis frequently had fever (92%) and irritability (84%) (Figure 1).
145	Clinical seizures were present in half of neonates. A bulging fontanelle was present in 22% overall and in
146	6/16 (38%) infants at Mbale but in only 2/21 (10%) at Mbarara, P=0.06. All other presenting signs
147	occurred in a similar proportion of neonates at each of the two sites.
148	Laboratory studies
149	Blood cultures grew an organism in 4/37 (14%) of neonates (Supplemental Table 2). Two grew
150	Staphylococcus aureus, and one each grew a Klebsiella species, a Bacillus species and Streptococcus
151	agalactiae. Due to testing limitations at the local microbiology laboratory, species-level identification of
152	some organisms was not performed. One of the neonates with S. aureus died shortly after hospital
153	admission. All 37 neonates had negative antigen testing for malaria. Thirty-six patients had a blood CMV
154	PCR performed; none was positive.
155	Seventeen of the 37 paenibacilliosis patients had a CSF WBC count reported. Four of the 17
156	(24%) neonates with an available CSF WBC count had a CSF WBC count $\ge$ 15: 20, 75, 75 and 80 x10 <sup>6</sup>
157	cells/L. The protein concentration was $\geq 1$ g/L in two of these four (50%) neonates (1.8, 5.4 g/L) and in
158	an additional 6 neonates (8/37, 22%) with normal or unavailable CSF WBC counts (1, 1, 1, 2.3, 3.4, 5
159	g/L). CSF and blood glucose concentrations were not available. No CSF culture grew bacteria in the local
160	laboratory.

161

## 162 *Treatment*

163	The choice of empirical therapy was chosen by the admitting healthcare worker and therefore
164	varied across the cohort. Most neonates with paenibacilliosis (26/37, 70%) were initially started on
165	intravenous ampicillin plus gentamicin. Eight (21%) were treated initially with a third-generation
166	cephalosporin (ceftriaxone or cefotaxime) along with either gentamicin (5, 13%), or an aminoglycoside,
167	ampicillin and cloxacillin (2, 7%). Three (8%) received ampicillin, cloxacillin and gentamicin as initial
168	therapy and 1 (3%) received ampicillin, gentamicin and ceftriaxone.
169	Antibiotic therapy was escalated to a broader antibiotic regimen for 9/37 (24%) neonates.
170	Antibiotic escalation occurred after a median of 3 days (IQR: 3, 3). This is common practice in these
171	hospitals, when the treating clinician does not see a good clinical response. Most commonly, ampicillin
172	was changed to a cephalosporin (5/9, 56%). In two cases each (2/9, 22%), cloxacillin was added to
173	ampicillin and gentamicin and in 1 case (1/9, 11`%) gentamicin was changed to a cephalosporin and
	ampicillin was continued
174	ampiennin was continued.
174 175	Outcomes
174 175 176	Outcomes The composite poor outcome of infant death, PIH or NDI was more common in neonates with
174 175 176 177	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with
174 175 176 177 178	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two
174 175 176 177 178 179	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following
174 175 176 177 178 179 180	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each
174 175 176 177 178 179 180 181	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each site, 2/16 (13%) at Mbale and 3/21 (14%) at Mbarara, P=1.00. Three patients progressed rapidly to death
174 175 176 177 178 179 180 181 182	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each site, 2/16 (13%) at Mbale and 3/21 (14%) at Mbarara, P=1.00. Three patients progressed rapidly to death prior to hospital discharge. Another infant remained critically ill during the hospital stay and was
174 175 176 177 178 179 180 181 182 183	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each site, 2/16 (13%) at Mbale and 3/21 (14%) at Mbarara, P=1.00. Three patients progressed rapidly to death prior to hospital discharge. Another infant remained critically ill during the hospital stay and was discharged to home against medical advice; this infant died shortly after discharge home. A fifth patient
174 175 176 177 178 179 180 181 182 183 184	<i>Outcomes</i> The composite poor outcome of infant death, PIH or NDI was more common in neonates with paenibacilliosis than those without, 11/37 (30%) vs. 79/594 (13%), P=0.012. Among neonates with paenibacilliosis, there was no difference in the frequency of the composite poor outcome between the two sites, 7/16 (44%) at Mbale and 4/21 (19%) at Mbarara, P=0.151 (Figure 2). Infant death following paenibacilliosis occurred in 5/37 (14%) and occurred in a similar proportion of neonates cared for at each site, 2/16 (13%) at Mbale and 3/21 (14%) at Mbarara, P=1.00. Three patients progressed rapidly to death prior to hospital discharge. Another infant remained critically ill during the hospital stay and was discharged to home against medical advice; this infant died shortly after discharge home. A fifth patient was treated with 5 days of ampicillin and gentamicin, was discharged home from the hospital in good

186	PIH was also more common among neonates with paenibacilliosis than those neonates without
187	paenibacilliosis, 5/37 (14%) vs. 3/594 (<1%), P<0.001. Additionally, PIH occurred following
188	paenibacilliosis more frequently at Mbale, 5/16 (31%), than at Mbarara, 0/21 (0%), P=0.010. Four of the
189	five (80%) neonates with Paenibacillus-associated PIH had an elevated CSF protein concentration but all
190	5/5 (100%) had a CSF WBC count < 100 x10 <sup>6</sup> cells/L at presentation (Table 2). Two required placement
191	of a ventricular peritoneal shunt, two were managed conservatively without surgery and one was referred
192	for neurosurgical evaluation but was lost to follow-up. Nineteen of the 32 (59%) paenibacilliosis
193	survivors had a developmental assessment performed at 6 months and 22/32 (69%) at 12 months; 29
194	(91%) had a developmental assessment at 6 or 12 months of age. Three of the 4 patients with
195	paenibacilliosis-associated PIH who remained in care had moderate/severe neurodevelopmental
196	impairment as assessed at 6- or 12- months of age (Table 3). One additional neonate (4%) who survived
197	without hydrocephalus had NDI at the last developmental assessment.
198	The three isolates of <i>P. thiaminolyticus</i> that were successfully cultured from infants with PIH
199	following NS were all non-susceptible to vancomycin (Table 4). Two of the three (67%) were resistant to
200	ampicillin. There are not interpretive criteria for the clinical significance of minimum inhibitory
201	concentrations (MIC) for ceftriaxone but 2 of the 3 had a very low MIC and the third had an MIC of 0.25
202	ug/mL, a concentration which is probably susceptible. <sup>19</sup>
203	Discussion

We describe the first cohort of neonates with sepsis due to *Paenibacillus species*; most infections
were due to *P. thiaminolyticus*. Signs of meningitis such as irritability, seizures and bulging fontanelle
were common at presentation. Eleven percent of neonates died during their original in-patient admission.
Poor outcomes were common among survivors: PIH developed in 16% and NDI was common.

*P. thiaminolyticus* has rarely been reported as a cause of human disease. The first case of human
 infection was reported in 2008 when an 80-year-old man undergoing hemodialysis developed bacteremia

210 due to P. thiaminolyticus.<sup>20</sup> He received 4 weeks of vancomycin and improved. A 33-year-old Swiss 211 woman experienced a surgical wound infection due to P. thiaminolyticus 7 days following an 212 abdominoplasty procedure.<sup>21</sup> The organism was identified on culture of an aspirate from an abdominal 213 wall fluid collection. She was treated with 2 weeks of unspecified intravenous antibiotics followed by 2 214 weeks of amoxicillin-clavulanate as definitive therapy and completely recovered. Finally, P. 215 thiaminolyticus was recovered on blood culture from a 25-day old neonate admitted to a hospital in the 216 United States of America due to cardiorespiratory arrest following 1 day of poor feeding and increased sleep.<sup>22</sup> Unfortunately, the neonate succumbed to her infection 4 days later. Post-mortem examination 217 218 revealed a soft brain with several areas of infarction but without clear signs of meningitis. Our finding 219 that 33 of 631 (5%) neonates evaluated for sepsis had P. thiaminolyticus detected using molecular 220 methods was unexpected and suggests that P. thiaminolyticus may be an underdiagnosed cause of 221 neonatal sepsis, meningitis, and PIH in Uganda.

222 Studies seeking to identify causative organisms for neonatal sepsis may fail to identify P. 223 thiaminolyticus for several reasons. First, this organism may have ecological niches that are not 224 universally distributed. We failed to find any evidence of *P. thiaminolyticus* presence in the vaginal 225 microbiome of 99 women residing in Mbale or Mbarara, Uganda at the time of delivery suggesting that 226 neonates may become colonized with the organism through environmental, rather than maternal sources.<sup>23</sup> It has been identified in fish from Lake Michigan in the United States,<sup>24</sup> and from the soil in India.<sup>25</sup> Other 227 species of *Paenibacillus* have been identified in the soil globally<sup>26-30</sup> and as a member of the human gut 228 229 microbiome.<sup>31</sup> Some species are known to infect honeybees<sup>32</sup> and, rarely, humans.<sup>33-35</sup> Neonates cared for 230 in industrialized or high-resource settings may have limited contact with environmental reservoirs of 231 Paenibacillus. Studies evaluating neonatal pathogens in high-resource settings may fail to identify 232 Paenibacillus because there are no neonatal infections in those cohorts caused by Paenibacillus.

Neonates who are born and live in environments where exposure to contaminated water and soil
is common could encounter *Paenibacillus* more frequently and at higher levels. It is possible that neonatal

235 infections due to *Paenibacillus* do occur globally but are not diagnosed in either high- or low-resource 236 settings due to the limitations of culture-based pathogen detection methods in neonates. Even common 237 neonatal pathogens can be missed when the blood volume used to inoculate the blood culture bottles is <1 mL.<sup>36,37</sup> Low sample volume will similarly have limited our ability to detect Paenibacillus in an infant 238 239 with paenibacillosis. Blood cultures are typically incubated for 5-7 days and CSF cultures for 2-5 days. 240 Paenibacillus may take 7-14 days to reach the level of detection using standard culture methods.<sup>38</sup> 241 Cultures may be deemed negative and the specimens discarded prior to sufficient time to detect 242 Paenibacillus elapsing. Studies attempting to diagnose the spectrum of pathogens causing disease in 243 neonatal sepsis may be improved by increasing the duration of specimen incubation beyond the standard 244 5-7 days or by using molecular methods to improve diagnostic yield.

245 In our prior work, we were able to grow *P. thiaminolyticus* from the CSF of 3 neonates with PIH 246 by inoculating the CSF into anaerobic lytic blood culture bottles. Anaerobic blood culture bottles are not 247 used as routine part of the evaluation of neonatal sepsis in most clinical settings but have been shown to increase the diagnostic yield of blood cultures for neonates with bacteremia.<sup>39</sup> Culture sensitivity for 248 249 fastidious organisms such as *Kingella kingae* is also known to be improved when synovial fluid is 250 incubated in a blood culture bottle.<sup>40,41</sup> The addition of an anaerobic blood culture bottle to the CSF 251 evaluation of neonates with sepsis may improve the diagnosis of infections due to Paenibacillus and 252 facultative anaerobes implicated in neonatal sepsis. Using these methods in all neonates with sepsis may 253 not be warranted if the prevalence of infections identified using them is low. However, in research 254 settings that attempt to describe the range of organisms infecting young infants expanding culture-based 255 techniques to include additional types of media could potentially reduce false negatives and allow for a 256 more complete description of the causative bacterial agents.

All of the neonates in our cohort with paenibacillosis were diagnosed using molecular methods.
The addition of a *Paenibacillus* PCR to the evaluation of neonatal sepsis could improve the diagnosis of
this emerging infection by providing a rapid, low-biomass way of identifying affected neonates. PCR and

other molecular methods have been shown to be useful for the diagnosis of other fastidious organisms
that cause disease in neonates such as *Mycoplasma hominis*,<sup>42</sup> *Ureaplasma parvum*,<sup>43</sup> *Leptotrichia amnionii*,<sup>44</sup> and *Sneathia amnii*.<sup>45</sup> Epidemiological studies of neonatal serious bacterial infections that
only use culture-based methods likely underestimate both the number and variety of infections caused by
bacteria.

265 The diagnosis of *Paenibacillus* infection is important for the care of neonates with sepsis due to 266 the high incidence of associated mortality and morbidity. In contrast to infections due Streptococcus 267 agalactiae (0%<sup>46</sup>-4%<sup>47</sup>), paenibacillosis resulted in PIH in 12% of cases. Meningitis due to E. coli causes 268 PIH in 18<sup>47</sup>-22%<sup>46</sup>. In our cohort, *Paenibacillus* conferred a similar risk of PIH as *E. coli* but was a more 269 common cause of infection in our cohort (data not shown). Thus, paenibacillosis may be a leading cause 270 of PIH in Uganda. It is unknown whether optimal treatment of neonatal paenibacillosis would reduce the 271 incidence of PIH or NDI in the region. We assessed NDI using the BSID-III. Although the BSID-III uses 272 age-based normative values generated from an American population, the tool has been shown to be a 273 valid means of comparing development for young African infants to each other but not to infants from 274 other regions of the world.<sup>48,49</sup> We found that NDI occurred following clinical neonatal sepsis in a similar 275 proportion of infants with and without paenibacilliosis.

276 The World Health Organization recommends using the combination of ampicillin and gentamicin 277 as the empirical antibiotic regimen for neonatal sepsis due to the coverage provided against *Streptococcus* 278 agalactiae (Group B streptococcus), Escherichia coli, and Listeria monocytogenes.<sup>50</sup> Regions where 279 antibiotic resistance is common or additional organisms are typical may need to use a broader spectrum regimen empirically.<sup>51,52</sup> Our discovery that *P. thiaminolyticus* could be a common cause of culture-280 281 negative sepsis in Uganda has important implications for empiric antibiotic selection. Antibiotic 282 susceptibility testing performed on the three isolates we successfully isolated from neonates with PIH 283 demonstrated resistance to ampicillin and vancomycin. We additionally identified the presence of several beta-lactamase genes which could confer resistance to ampicillin.<sup>53</sup> Prior studies have found that 284

285 resistance to ampicillin, vancomycin, clindamycin and tetracycline is common in Paenibacillus species.<sup>21,54</sup> Because there are few clinical reports of *P. thiaminolyticus*, it is unknown how often 286 287 resistance occurs or what antibiotic regimens would maximize the likelihood of a good outcome. 288 Inappropriate empirical antibiotic therapy has been associated with worse outcomes for neonatal sepsis. <sup>55-57</sup> These studies assume that an appropriate antibiotic is ultimately administered within 1-3 days 289 of symptom onset.<sup>58</sup> Unfortunately, *P. thiaminolyticus* can be difficult to recover using culture and will be 290 291 consistently missed in Uganda and other parts of the world where neonatal sepsis is common.<sup>59,60</sup> Thus, it 292 is likely that many infected neonates do not receive effective antimicrobial therapy at all, thus increasing 293 the risk of mortality and serious sequelae, including PIH. Incorporating the possibility of a difficult-to-294 culture organism into antibiotic guidelines and protocols has the potential to improve outcomes. Our 295 findings suggest that the combination of a third-generation cephalosporin and gentamicin would be 296 preferred over ampicillin and gentamicin as an empiric antibiotic regimen for neonatal sepsis in Uganda 297 especially when meningitis is suspected. A prior study of soil Paenibacillus species' suggests that ~70% 298 of isolates are susceptible to ceftriaxone, an antibiotic that has good penetration into the central nervous system.<sup>54</sup> Gentamicin is less reliable at achieving therapeutic concentrations in the central nervous system, 299 300 especially if an abscess is present, but resistance appears to be quite uncommon.<sup>54,61</sup> Antibiotic 301 susceptibility testing should be performed to guide antibiotic management in individual cases of 302 paenibacilliosis. Performing antibiotic susceptibility testing on a larger number of isolates will be 303 important to improve our understanding of how best to care for neonates with these infections. 304 The possibility of antibiotic resistance should be considered when antibiotics are chosen to treat a 305 neonate with paenibacilliosis.<sup>62</sup> In particular, the WHO-recommended first-line antibiotic regimen for the 306 treatment of neonatal sepsis (ampicillin plus gentamicin), is unlikely to be effective for P. 307 thiaminolyticus. Vancomycin is commonly used for gram positive central nervous system (CNS) 308 infections and is the drug-of-choice for CNS infections due to Bacillus species but should not be used 309 empirically for treatment of *Paenibacillus* infections.<sup>63</sup> It is possible that alternate antibiotic regimens 310 may be optimal for treatment of this novel infection. Because this organism may be an important

311 pathogen in the developing world, any antibiotic consideration would need to achieve therapeutic

312 concentrations in the CNS, be inexpensive, easily administered, and well tolerated with few side effects.

313 Nutritional interventions may also be important adjunctive treatments for *P. thiaminolyticus* 314 infections. This organism produces thiaminase, an uncommon bacterial enzyme which has the potential to 315 reduce thiamine levels.<sup>24</sup> Recent studies have failed to show a mortality benefit of the combination of 316 thiamine, vitamin C with and without hydrocortisone in mortality outcomes for adults with sepsis.<sup>64-66</sup> 317 However, in a retrospective analysis, thiamine supplementation improved survival for adults with 318 hospital-acquired pneumonia.<sup>67</sup> Thiamine supplementation may yet have a role for certain types of 319 infection, in cases when sepsis is caused by a thiamine-consuming organism or when pre-existing 320 thiamine deficiency exists.<sup>68-70</sup> Furthermore, thiamine supplementation may improve neurodevelopmental 321 outcomes or reduce the likelihood of other sequelae, such as PIH, following neonatal sepsis even if it does 322 not infer a survival benefit.<sup>71,72</sup> Studies evaluating the role of thiamine supplementation as adjunctive 323 therapy for neonatal sepsis due to thiaminase-producing P. thiaminolyticus are needed.

324 An important area of future research will be to define the qPCR level that is clinically significant. 325 In this report, we included all neonates who had any *Paenibacillus* result. It is possible that some infants 326 included had infections due to other organisms, or even non-infectious reasons for presenting with clinical 327 signs consistent with infection. Additionally, the outcomes that we present following neonatal 328 paenibacilliosis may reflect inadequate antibiotic therapy being more common among neonates with 329 Paenibacillus detected than those without. Infants with paenibacilliosis may be more likely to receive 330 ineffective antibiotic therapy than infants without paenibacilliosis. This could explain some of the 331 increased frequency of poor outcomes in infants with Paenibacillus detected. Since the causative 332 pathogen was unknown in the majority of non-paenibacilliosis cases, we were not able to assess 333 antibiotic-microbe concordance in order to assess for this possibility.

334

# 335 Conclusion

336	Paenibacillus species was identified in 6% of neonates with signs of sepsis who presented to two
337	Ugandan referral hospitals; most of these were P. thiaminolyticus. Improved diagnostics for neonatal
338	sepsis are urgently needed in the region. Optimal antibiotic treatment for this infection is unknown but
339	ampicillin and vancomycin will be ineffective in many cases. The role of thiamine supplementation as
340	adjunctive therapy is unknown but rational to consider.
341	
342	Acknowledgements
343	This study and the parent neonatal sepsis study were funded by the National Institutes of Health under
344	1DP1HD086071(S.J.S) and 1R01AI145057 (S.J.S). J.E.E. was supported by National Center for
345	Advancing Translational Sciences grant #KL2 TR002015.
346	
347	
348	
349	
350	
351	
352	
353	
354	

355

- 356 Table 1. Demographics of neonates with clinical sepsis due with and without *Paenibacillus*
- 357 *thiaminolyticus* detected by qPCR.

	Paenibacillus	Paenibacillus	Р
	PCR Positive	PCR Negative	
	N=37 (6%)	N=594 (94%)	
Median age at sepsis presentation, days (25 <sup>th</sup> ,	3 (1, 7)	2 (1, 4)	0.129
75 <sup>th</sup> percentiles)			
<3 days	22 (61)	433 (73)	
3-7 days	6 (17)	55 (9)	
8-14 days	7 (19)	46 (8)	
>14 days	1 (3)	59 (10)	
Median gestational age at birth, weeks (25 <sup>th</sup> ,	39 (38, 40)	40 (39, 41)	0.266
75 <sup>th</sup> percentiles)			
Median birth weight, g (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	3200 (3000,	3200 (2900,	0.505
	3500)	3500	
Sex			
Female	20 (54)	335 (56)	0.865
Male	17 (46)	259 (44)	
Maternal HIV status			0.209
Positive	4 (11)	29 (5)	
Negative	31 (84)	539 (91)	
Unknown	2 (5)	27 (5)	
Median maternal age, years (25 <sup>th</sup> , 75 <sup>th</sup>	26 (23, 30)	24 (21, 29)	0.443
percentiles)			

Median maternal parity (25 <sup>th</sup> , 75 <sup>th</sup> percentiles)	2 (1, 4)	2 (1, 4)	0.402
Maternal fever during pregnancy	19 (51)	333 (51)	0.608
Maternal fever during labor	8 (22)	164 (28)	0.487
Delivery location			
Healthcare	29 (78)	555 (94)	0.003*
Hospital	21 (57)	422 (71)	
Health center	7 (19)	113 (19)	
Clinic	1 (3)	20 (3)	
Home	8 (22)	36 (6)	
Delivery mode			0.166
Vaginal	27 (73)	361 (61)	
C-section	10 (27)	230 (39)	
Rupture of membranes >18 hours	8 (24)	101 (19)	0.495
Umbilical cord care			
None	23 (62)	475 (81)	0.011†
Any substance	14 (38)	113 (19)	
Saliva	6 (16)	41 (7)	
Cosmetic	6 (16)	35 (6)	
Plant material	2 (5)	28 (5)	
Other	0 (0)	9 (10)	
Feeding method			0.123
Exclusively breast fed	34 (92)	561 (94)	
Breast milk and water	1 (3)	1 (<1)	
Breast milk and replacement feeding	1 (3)	20 (3)	
Replacement feeding	1 (3)	4 (1)	

	Unknown	0 (0)	8 (1)	
Location				0.085
	Mbarara	21 (57)	244 (41)	
	Mbale	16 (43)	350 (59)	

358 \*Fisher's exact test comparing the proportion of patients with and without Paenibacillus detected who

359 were born at home vs. in a healthcare facility (clinic, health centre or hospital); †Fisher's exact test

360 comparing the proportion of patients with and without Paenibacillus detected who had any vs. no

361 substances applied to the umbilical cord stump.

	1	2	3	4	5
Age at	8-14 days	< 3 days	8-14 days	3-7 days	3-7 days
presentation					
Sex	Female	Male	Male	Male	Male
Birth	Home	Home	Home	Home	Home
location					
Cord care	Cosmetic powder	Cosmetic powder	Vaseline	None	None
Presenting	Fever, poor feeding,	Fever, poor feeding, irritability,	Fever, poor feeding,	Fever, poor feeding,	Fever, poor
signs	irritability, bulging	bulging fontanelle, lethargy,	irritability, bulging	irritability, lethargy,	feeding, irritability,
	fontanelle, lethargy,	seizure, hypertonia	fontanelle, lethargy,	vomiting, seizure,	lethargy, seizure,
	seizure, umbilical		respiratory distress,	hypotonia	stiff neck,
	discharge		hypotonia		hypertonia
CSF cell	≤5	75	80	≤5	≤5
count, $10^6$					
cells/L					
CSF protein,	3.4	1.8	0.5	1	2.3
g/L					

362 Table 2. Description of neonates who developed postinfectious hydrocephalus following neonatal sepsis with *P. thiaminolyticus* detected by qPCR

Blood	Negative	Negative	Negative	Negative	Negative
culture result					
Admission	125	148	138	136	131
heart rate,					
beats/minute					
Admission	36	51	67	59	47
respiratory					
rate,					
breaths/minu					
te					
Initial	3 days	2 days ampicillin/gentamicin	2 days	7 days	9 days
antibiotic	ampicillin/gentamici		ampicillin/gentamici	ceftriaxone/gentami	ampicillin/gentami
treatment	n,		n	cin	cin
Additional	11 days	7 days ceftriaxone/gentamicin, 14	4 days		
antibiotic	ceftriaxone/gentami	days ceftriaxone/amikacin	cefotaxime/gentamic		
treatment	cin	14 days enteral	in, 14 days		
		amoxicillin/ciprofloxacin/metronida	ceftriaxone/amikacin		
		zole			

Hydrocephal	None	Shunted	Shunted	None	None
us treatment					
6-month	Moderate cognitive	Not seen	Moderate cognitive	Normal	Not seen
outcome	and motor		and motor		
12-month	Not seen	Moderate cognitive and motor	Not seen	Normal	Not seen
outcome		impairment			

Table 3. Developmental outcomes for survivors of neonatal sepsis with P. thiaminolyticus detected by

# qPCR

	6 months	12 months	Last follow up
	N=19 (%)	N=22 (%)	N=29 (%)
Scaled cognitive score, mean $\pm$ SD	11 ± 5	13 ± 3	13 ± 5
Moderate/severe impairment	2 (11)	1 (5)	3 (10)
Scaled fine motor score, mean $\pm$ SD	12 ± 5	12 ± 3	12 ± 5
Moderate/severe impairment	2 (11)	1 (5)	2 (7)
Scaled gross motor score, mean $\pm$ SD	$11 \pm 4$	$10 \pm 4$	9 ± 4
Moderate/severe impairment	2 (11)	2 (9)	4 (14)
Scaled receptive communication score, mean	$10 \pm 4$	10 ± 3	10 ± 4
$\pm$ SD			
Moderate/severe impairment	2 (11)	1 (5)	2 (7)
Scaled expressive communication score,	9 ± 4	$10 \pm 2$	10 ± 3
mean $\pm$ SD			
Moderate/severe impairment	2 (11)	0 (0)	3 (10)

Table 4. E-test Antibiotic susceptibility testing results for P. thiaminolyticus isolates obtained from 3

	Mbale		Mbale2		Mbale3	
	MIC (µg/mL)	Interpretation	MIC (µg/mL)	Interpretation	MIC (µg/mL)	Interpretation
Ampicillin	0.12	S	1	R	0.5	R
Ceftriaxone	0.03	**	0.25	**	0.06	**
Ciprofloxacin	0.12	S	0.12	S	0.12	S
Clindamycin	1	I	1	I	4	R
Gentamicin	2	S	2	S	2	S
Penicillin	0.12	S	0.5	R	0.25	R
Meropenem	0.25	S	0.5	S	0.5	S
Tetracycline	0.5	S	2	S	2	S
Vancomycin	8	Nonsusceptible	8	Nonsusceptible	8	Nonsusceptible

infants with post-infectious hydrocephalus as a sequela of neonatal sepsis.

MIC: minimum inhibitory concentration; S: susceptible; R: resistant; I: intermediate

Figure 1. Presenting signs and outcomes for neonates with *Paenibacillus thiaminolyticus* detected by qPCR during clinical sepsis.



Number of neonates presenting to each site with each sign of infection. Numbers at the end of each bar indicate the proportion of neonates at each site who had the corresponding sign of infection. Neonates with the composite poor outcome of death, postinfectious hydrocephalus or moderate/severe neurodevelopmental impairment are indicated in red.

Figure 2. Outcomes for neonates with clinical sepsis with *Paenibacillus* negative (PN) and *Paenibacillus* positive (PP) qPCR results for *Paenibacillus thiaminolyticus* detection in the CSF at both sites and at Mbarara and Mbale.



# Supplemental Table 1. *Paenibacillus* genus and *Paenibacillus thiaminolyticus* qPCR results from blood and cerebrospinal fluid.

	Cerebros	Cerebrospinal Fluid		Blood		
Subject	Paenibacillus	Paenibacillus	Paenibacillus	Paenibacillus		
	genus	thiaminolyticus	genus	thiaminolyticus		
1	51,846	909	ND	ND		
2	419,144	926,763	ND	ND		
3	540,471	905,393	ND	ND		
4	335	509	ND	ND		
5	ND	255,011	ND	ND		
6	55	1749	ND	ND		
7	62	ND	ND	ND		
8	118	ND	ND	ND		
9	147	ND	ND	ND		
10	151	ND	ND	ND		
11	152	1585	ND	ND		
12	178	1217	ND	ND		
13	204	ND	ND	ND		
14	208	2048	ND	ND		
15	212	2225	ND	ND		
16	240	ND	ND	ND		
17	245	1606	ND	ND		
18	280	ND	ND	ND		
19	324	ND	ND	ND		
20	363	3704	ND	ND		
21	462	4537	ND	ND		
22	742	1930	ND	ND		
23	955	1171	ND	ND		
24	1077	2848	ND	ND		
25	1094	6549	ND	ND		
26	1456	ND	ND	ND		
27	22,561	1427	ND	ND		
28	27,897	1437	ND	ND		
29	30,023	1011	ND	ND		
30	32,109	43,556	ND	ND		
31	68,263	2505	ND	ND		
32	140,435	12,387	5846	12,541		
33	173,836	ND	ND	ND		
34	300,260	ND	ND	ND		
35	ND	827	ND	ND		
36	ND	ND	ND	699		
37	ND	ND	ND	214		

ND: not detected

Supplemental Table 2. Results of blood polymerase chain reaction tests for cytomegalovirus and blood cultures for neonates with and without *Paenibacillus* detected.

	Paenibacillus PCR	Paenibacillus
	Positive	PCR Negative
	N=37 (%)	N=594 (%)
CMV		
Positive	0 (0)	15 (3)
Negative	36 (97)	564 (95)
Unknown	1 (3)	15 (3)
Blood culture	5 (15)	82 (14)
Not done	3 (8)	14 (2)
No growth	29 (78)	498 (84)
Staphylococcus aureus	2 (5)	48 (8)
Klebsiella species	1 (3)	8 (1)
Bacillus species	1 (3)	4 (1)
Streptococcus agalactiae	1 (3)	(0)
Micrococcus species		9 (2)
Corynebacterium species		4 (1)
Escherichia coli		3 (1)
Unspecified coliform		3 (1)
Coagulase-negative staphylococcus		2 (<1)
Haemophilus species		1 (<1)

# References

- 1. Taylor AW, Blau DM, Bassat Q, et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. Lancet Glob Health 2020;8(7):e909-e919. (In eng). DOI: 10.1016/S2214-109X(20)30205-9.
- 2. Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child 2021 (In eng). DOI: 10.1136/archdischild-2020-320217.
- 3. Shim SY, Cho SJ, Park EA. Neurodevelopmental Outcomes at 18-24 Months of Corrected Age in Very Low Birth Weight Infants with Late-onset Sepsis. J Korean Med Sci 2021;36(35):e205. (In eng). DOI: 10.3346/jkms.2021.36.e205.
- 4. Shadbolt R, We MLS, Kohan R, et al. Neonatal Staphylococcus Aureus Sepsis: a 20year Western Australian experience. J Perinatol 2022 (In eng). DOI: 10.1038/s41372-022-01440-3.
- 5. Warf BC, Dagi AR, Kaaya BN, Schiff SJ. Five-year survival and outcome of treatment for postinfectious hydrocephalus in Ugandan infants. J Neurosurg Pediatr 2011;8(5):502-8. (In eng). DOI: 10.3171/2011.8.PEDS11221.
- 6. Al-Matary A, Al Sulaiman M, Al-Otaiby S, Qaraqei M, Al-Matary M. Association between the timing of antibiotics administration and outcome of neonatal sepsis. J Infect Public Health 2022;15(6):643-647. (In eng). DOI: 10.1016/j.jiph.2022.05.004.
- 7. Saha SK, Schrag SJ, El Arifeen S, et al. Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study. Lancet 2018;392(10142):145-159. (In eng). DOI: 10.1016/S0140-6736(18)31127-9.
- 8. Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 2007;119(5):891-6. (In eng). DOI: 10.1542/peds.2006-0440.
- 9. Obiero CW, Gumbi W, Mwakio S, et al. Detection of pathogens associated with earlyonset neonatal sepsis in cord blood at birth using quantitative PCR. Wellcome Open Res 2022;7:3. (In eng). DOI: 10.12688/wellcomeopenres.17386.2.
- 10. Velaphi SC, Westercamp M, Moleleki M, et al. Surveillance for incidence and etiology of early-onset neonatal sepsis in Soweto, South Africa. PLoS One 2019;14(4):e0214077. (In eng). DOI: 10.1371/journal.pone.0214077.
- 11. Fuchs A, Bielicki J, Mathur S, Sharland M, Van Den Anker JN. Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children. Paediatr Int Child Health 2018;38(sup1):S3-S15. (In eng). DOI: 10.1080/20469047.2017.1408738.
- 12. Labi AK, Enweronu-Laryea CC, Nartey ET, et al. Bloodstream Infections at Two Neonatal Intensive Care Units in Ghana: Multidrug Resistant Enterobacterales Undermine the Usefulness of Standard Antibiotic Regimes. Pediatr Infect Dis J 2021;40(12):1115-1121. (In eng). DOI: 10.1097/INF.00000000003284.
- 13. Nebbioso A, Ogundipe OF, Repetto EC, et al. When first line treatment of neonatal infection is not enough: blood culture and resistance patterns in neonates requiring second line antibiotic therapy in Bangui, Central African Republic. BMC Pediatr 2021;21(1):570. (In eng). DOI: 10.1186/s12887-021-02911-w.
- 14. Zamarano H, Musinguzi B, Kabajulizi I, et al. Bacteriological profile, antibiotic susceptibility and factors associated with neonatal Septicaemia at Kilembe mines hospital, Kasese District Western Uganda. BMC Microbiol 2021;21(1):303. (In eng). DOI: 10.1186/s12866-021-02367-z.

- 15. Paulson JN, Williams BL, Hehnly C, et al. infection with frequent viral coinfection contributes to postinfectious hydrocephalus in Ugandan infants. Sci Transl Med 2020;12(563) (In eng). DOI: 10.1126/scitranslmed.aba0565.
- 16. Isaacs AM, Morton SU, Movassagh M, et al. Immune activation during. iScience 2021;24(4):102351. (In eng). DOI: 10.1016/j.isci.2021.102351.
- 17. Morton SU, Hehnly C, Burgoine K, et al. *Paenibacillus* Infection Causes Neonatal Sepsis and Subsequent Postinfectious Hydrocephalus in Ugandan Infants. . SSRN; 2022.
- 18. Drotar D, Olness K, Wiznitzer M, et al. Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. Pediatrics 1997;100(1):E5. (In eng). DOI: 10.1542/peds.100.1.e5.
- 19. Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007;60(3):555-67. (In eng). DOI: 10.1093/jac/dkm213.
- 20. Ouyang J, Pei Z, Lutwick L, et al. Case report: Paenibacillus thiaminolyticus: a new cause of human infection, inducing bacteremia in a patient on hemodialysis. Ann Clin Lab Sci 2008;38(4):393-400. (In eng).
- 21. Di Micco R, Schneider M, Nüesch R. Postoperative Paenibacillus thiaminolyticus Wound Infection, Switzerland. Emerg Infect Dis 2021;27(7):1984-1986. (In eng). DOI: 10.3201/eid2707.203348.
- 22. Hunt B, Rogers C, Blais RM, Adachi K, Sathyavagiswaran L. Paenibacillus Sepsis and Meningitis in a Premature Infant: A Case Report. Am J Forensic Med Pathol 2021;42(1):96-98. (In eng). DOI: 10.1097/PAF.0000000000000610.
- 23. Movassagh M, Bebell LM, Burgoine K, et al. Vaginal microbiome topic modeling of laboring Ugandan women with and without fever. NPJ Biofilms Microbiomes 2021;7(1):75. (In eng). DOI: 10.1038/s41522-021-00244-1.
- 24. Richter CA, Wright-Osment MK, Zajicek JL, Honeyfield DC, Tillitt DE. Quantitative polymerase chain reaction (PCR) assays for a bacterial thiaminase I gene and the thiaminase-producing bacterium Paenibacillus thiaminolyticus. J Aquat Anim Health 2009;21(4):229-38. (In eng). DOI: 10.1577/H07-054.1.
- Dhawan S, Singh R, Kaur R, Kaur J. A β-mannanase from Paenibacillus sp.: Optimization of production and its possible prebiotic potential. Biotechnol Appl Biochem 2016;63(5):669-678. (In eng). DOI: 10.1002/bab.1419.
- 26. Dsouza M, Taylor MW, Turner SJ, Aislabie J. Genome-based comparative analyses of Antarctic and temperate species of Paenibacillus. PLoS One 2014;9(10):e108009. (In eng). DOI: 10.1371/journal.pone.0108009.
- 27. Chauhan NS, Joseph N, Shaligram S, et al. Paenibacillus oleatilyticus sp. nov., isolated from soil. Arch Microbiol 2022;204(8):516. (In eng). DOI: 10.1007/s00203-022-03116-0.
- da Silva FKL, de Sa Alexandre AR, Casas AA, et al. Increased production of chitinase by a Paenibacillus illinoisensis isolated from Brazilian coastal soil when immobilized in alginate beads. Folia Microbiol (Praha) 2022 (In eng). DOI: 10.1007/s12223-022-00992-3.
- 29. Kumar S, Ujor VC. Complete Genome Sequence of Paenibacillus polymyxa DSM 365, a Soil Bacterium of Agricultural and Industrial Importance. Microbiol Resour Announc 2022;11(6):e0032922. (In eng). DOI: 10.1128/mra.00329-22.
- 30. Lee M, Ten LN, Baek SH, Im WT, Aslam Z, Lee ST. Paenibacillus ginsengisoli sp. nov., a novel bacterium isolated from soil of a ginseng field in Pocheon Province, South Korea. Antonie Van Leeuwenhoek 2007;91(2):127-35. (In eng). DOI: 10.1007/s10482-006-9102-x.

- 31. Dornelles LV, Procianoy RS, Roesch LFW, et al. Meconium microbiota predicts clinical early-onset neonatal sepsis in preterm neonates. J Matern Fetal Neonatal Med 2022;35(10):1935-1943. (In eng). DOI: 10.1080/14767058.2020.1774870.
- 32. Dang T, Loll B, Müller S, et al. Molecular basis of antibiotic self-resistance in a bee larvae pathogen. Nat Commun 2022;13(1):2349. (In eng). DOI: 10.1038/s41467-022-29829-w.
- 33. DeLeon SD, Welliver RC. Paenibacillus alvei Sepsis in a Neonate. Pediatr Infect Dis J 2016;35(3):358. (In eng). DOI: 10.1097/INF.000000000001003.
- 34. Zhang E, Lu H, Liu Q, et al. Paenibacillus assamensis in Joint Fluid of Man with Suspected Tularemia, China. Emerg Infect Dis 2018;24(8):1589-1591. (In eng). DOI: 10.3201/eid2408.180260.
- 35. Wenzler E, Kamboj K, Balada-Llasat JM. Severe Sepsis Secondary to Persistent Lysinibacillus sphaericus, Lysinibacillus fusiformis and Paenibacillus amylolyticus Bacteremia. Int J Infect Dis 2015;35:93-5. (In eng). DOI: 10.1016/j.ijid.2015.04.016.
- 36. Isaacman DJ, Karasic RB, Reynolds EA, Kost SI. Effect of number of blood cultures and volume of blood on detection of bacteremia in children. J Pediatr 1996;128(2):190-5. (In eng). DOI: 10.1016/s0022-3476(96)70388-8.
- 37. Kellogg JA, Ferrentino FL, Goodstein MH, Liss J, Shapiro SL, Bankert DA. Frequency of low level bacteremia in infants from birth to two months of age. Pediatr Infect Dis J 1997;16(4):381-5. (In eng). DOI: 10.1097/00006454-199704000-00009.
- 38. Hehnly C, Zhang L, Paulson JN, et al. Complete Genome Sequences of the Human Pathogen Paenibacillus thiaminolyticus Mbale and Type Strain P. thiaminolyticus NRRL B-4156. Microbiol Resour Announc 2020;9(15) (In eng). DOI: 10.1128/MRA.00181-20.
- 39. Messbarger N, Neemann K. Role of Anaerobic Blood Cultures in Neonatal Bacteremia. J Pediatric Infect Dis Soc 2018;7(3):e65-e69. (In eng). DOI: 10.1093/jpids/pix088.
- 40. Birgisson H, Steingrimsson O, Gudnason T. Kingella kingae infections in paediatric patients: 5 cases of septic arthritis, osteomyelitis and bacteraemia. Scand J Infect Dis 1997;29(5):495-8. (In eng). DOI: 10.3109/00365549709011861.
- 41. Yagupsky P, Dagan R, Howard CW, Einhorn M, Kassis I, Simu A. High prevalence of Kingella kingae in joint fluid from children with septic arthritis revealed by the BACTEC blood culture system. J Clin Microbiol 1992;30(5):1278-81. (In eng). DOI: 10.1128/jcm.30.5.1278-1281.1992.
- 42. Che G, Liu F, Chang L, Lai S, Teng J, Yang Q. Mycoplasma hominis Meningitis Diagnosed by Metagenomic Next-Generation Sequencing in a Preterm Newborn: a Case Report and Literature Review. Lab Med 2022 (In eng). DOI: 10.1093/labmed/Imac078.
- 43. Qin L, Li YH, Cao XJ, et al. Clinical metagenomic sequencing for rapid diagnosis of neonatal meningitis caused by Ureaplasma parvum: A case report. Medicine (Baltimore) 2022;101(4):e28662. (In eng). DOI: 10.1097/MD.00000000028662.
- 44. Decroix V, Goudjil S, Kongolo G, Mammeri H. 'Leptotrichia amnionii', a newly reported cause of early onset neonatal meningitis. J Med Microbiol 2013;62(Pt 5):785-788. (In eng). DOI: 10.1099/jmm.0.051870-0.
- 45. Vitorino P, Varo R, Castillo P, et al. Sneathia amnii and Maternal Chorioamnionitis and Stillbirth, Mozambique. Emerg Infect Dis 2019;25(8):1614-1616. (In eng). DOI: 10.3201/eid2508.190526.
- 46. Kralik SF, Kukreja MK, Paldino MJ, Desai NK, Vallejo JG. Comparison of CSF and MRI Findings among Neonates and Infants with. AJNR Am J Neuroradiol 2019;40(8):1413-1417. (In eng). DOI: 10.3174/ajnr.A6134.
- 47. Xu M, Hu L, Huang H, et al. Etiology and Clinical Features of Full-Term Neonatal Bacterial Meningitis: A Multicenter Retrospective Cohort Study. Front Pediatr 2019;7:31. (In eng). DOI: 10.3389/fped.2019.00031.

- 48. Cromwell EA, Dube Q, Cole SR, et al. Validity of US norms for the Bayley Scales of Infant Development-III in Malawian children. Eur J Paediatr Neurol 2014;18(2):223-30. (In eng). DOI: 10.1016/j.ejpn.2013.11.011.
- 49. Pendergast LL, Schaefer BA, Murray-Kolb LE, et al. Assessing development across cultures: Invariance of the Bayley-III Scales Across Seven International MAL-ED sites. Sch Psychol Q 2018;33(4):604-614. (In eng). DOI: 10.1037/spq0000264.
- 50. Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics--systematic review and meta-analysis. Arch Dis Child 2013;98(2):146-54. (In eng). DOI: 10.1136/archdischild-2012-302033.
- 51. Thaver D, Ali SA, Zaidi AK. Antimicrobial resistance among neonatal pathogens in developing countries. Pediatr Infect Dis J 2009;28(1 Suppl):S19-21. (In eng). DOI: 10.1097/INF.0b013e3181958780.
- 52. Dharmapalan D, Shet A, Yewale V, Sharland M. High Reported Rates of Antimicrobial Resistance in Indian Neonatal and Pediatric Blood Stream Infections. J Pediatric Infect Dis Soc 2017;6(3):e62-e68. (In eng). DOI: 10.1093/jpids/piw092.
- 53. C H, A S, P S, et al. Type IV pili is a critical virulence factor in clinical isolates of Paenibacillus thiaminolyticus. bioRxiv; 2022.
- 54. Sáez-Nieto JA, Medina-Pascual MJ, Carrasco G, et al. spp. isolated from human and environmental samples in Spain: detection of 11 new species. New Microbes New Infect 2017;19:19-27. (In eng). DOI: 10.1016/j.nmni.2017.05.006.
- 55. Chu SM, Hsu JF, Lai MY, et al. Risk Factors of Initial Inappropriate Antibiotic Therapy and the Impacts on Outcomes of Neonates with Gram-Negative Bacteremia. Antibiotics (Basel) 2020;9(4) (In eng). DOI: 10.3390/antibiotics9040203.
- 56. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ. Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2004;25(9):735-41. (In eng). DOI: 10.1086/502469.
- 57. Thaden JT, Ericson JE, Cross H, et al. Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants. Pediatr Infect Dis J 2015 (In ENG). DOI: 10.1097/INF.00000000000850.
- 58. Hsu JF, Chu SM, Wang HC, et al. Multidrug-Resistant Healthcare-Associated Infections in Neonates with Severe Respiratory Failure and the Impacts of Inappropriate Initial Antibiotic Therap. Antibiotics (Basel) 2021;10(4) (In eng). DOI: 10.3390/antibiotics10040459.
- 59. Kiwanuka J, Bazira J, Mwanga J, et al. The microbial spectrum of neonatal sepsis in Uganda: recovery of culturable bacteria in mother-infant pairs. PLoS One 2013;8(8):e72775. (In eng). DOI: 10.1371/journal.pone.0072775.
- 60. Popescu CR, Cavanagh MMM, Tembo B, et al. Neonatal sepsis in low-income countries: epidemiology, diagnosis and prevention. Expert Rev Anti Infect Ther 2020;18(5):443-452. (In eng). DOI: 10.1080/14787210.2020.1732818.
- 61. Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs 2013;15(2):93-117. (In eng). DOI: 10.1007/s40272-013-0017-5.
- 62. Guardabassi L, Christensen H, Hasman H, Dalsgaard A. Members of the genera Paenibacillus and Rhodococcus harbor genes homologous to enterococcal glycopeptide resistance genes vanA and vanB. Antimicrob Agents Chemother 2004;48(12):4915-8. (In eng). DOI: 10.1128/AAC.48.12.4915-4918.2004.
- 63. Tsai AL, Hsieh YC, Chen CJ, et al. Investigation of a cluster of Bacillus cereus bacteremia in neonatal care units. J Microbiol Immunol Infect 2022;55(3):494-502. (In eng). DOI: 10.1016/j.jmii.2021.07.008.

- 64. Ap GR, Daga MK, Mawari G, et al. Effect of Supplementation of Vitamin C and Thiamine on the Outcome in Sepsis: South East Asian Region. J Assoc Physicians India 2022;70(3):11-12. (In eng).
- 65. Na W, Shen H, Li Y, Qu D. Hydrocortisone, ascorbic acid, and thiamine (HAT) for sepsis and septic shock: a meta-analysis with sequential trial analysis. J Intensive Care 2021;9(1):75. (In eng). DOI: 10.1186/s40560-021-00589-x.
- 66. Sevransky JE, Rothman RE, Hager DN, et al. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. JAMA 2021;325(8):742-750. (In eng). DOI: 10.1001/jama.2020.24505.
- 67. Zhang L, Li S, Lu X, et al. Thiamine May Be Beneficial for Patients With Ventilator-Associated Pneumonia in the Intensive Care Unit: A Retrospective Study Based on the MIMIC-IV Database. Front Pharmacol 2022;13:898566. (In eng). DOI: 10.3389/fphar.2022.898566.
- 68. Li T, Bai J, Du Y, et al. Thiamine pretreatment improves endotoxemia-related liver injury and cholestatic complications by regulating galactose metabolism and inhibiting macrophage activation. Int Immunopharmacol 2022;108:108892. (In eng). DOI: 10.1016/j.intimp.2022.108892.
- 69. Raj KM, Baranwal AK, Attri SV, et al. Thiamine Status in Children with Septic Shock from a Developing Country: A Prospective Case-Control Study. J Trop Pediatr 2021;67(1) (In eng). DOI: 10.1093/tropej/fmaa107.
- 70. Donnino MW, Andersen LW, Chase M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med 2016;44(2):360-7. (In eng). DOI: 10.1097/CCM.00000000001572.
- 71. Measelle JR, Baldwin DA, Gallant J, et al. Thiamine supplementation holds neurocognitive benefits for breastfed infants during the first year of life. Ann N Y Acad Sci 2021;1498(1):116-132. (In eng). DOI: 10.1111/nyas.14610.
- 72. Sambon M, Wins P, Bettendorff L. Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. Int J Mol Sci 2021;22(11) (In eng). DOI: 10.3390/ijms22115418.